Sector Expert: Alex Arfaei

BMO Capital Markets



Recent Quotes

"With a diverse pipeline, including a number of first-in-class drugs in high-potential markets, MRK has significant potential growth drivers."

— Alex Arfaei, BMO Capital Markets (2/15/13)
more >

"MRK's MK-8931 is a promising drug that seems to be very effective at lowering beta-amyloid."

— Alex Arfaei, BMO Capital Markets (12/3/12)
more >

"MRK is well positioned for steady long-term growth."

— Alex Arfaei, BMO Capital Markets (10/28/12)
more >

"MRK is well positioned for steady, long-term growth."

— Alex Arfaei, BMO Capital Markets (8/26/12)
more >

"MRK's amended deal with AZ boosts its profit and loss statement."

— Alex Arfaei, BMO Capital Markets (7/2/12)
more >



Due to permission requirements, not all quotes are shown.